Shares in Morphosys AG surged by more than 17 percent during trading Thursday morning on news of a deal with Celgene Corp. for its anti-CD38 multiple myeloma antibody MOR202, worth an immediate €127 million (US$165.5 million) and which could be worth up to €628 million in total.
Complix NV raised €12 million (US$15.6 million) in a Series B round to fund development of small-protein therapeutics based on its alphabody scaffold platform.
Vasopharm GmbH raised €5 million (US$6.5 million) in new investment to fund preparations for a Phase III trial of VAS203, an allosteric inhibitor of nitric oxide (NO) synthase in development for treating traumatic brain injury (TBI).
Cardio3 Biosciences SA is the third European biotechnology company to dip its toes in the initial public offering (IPO) waters this year. The Belgian stem cell therapy developer is seeking up to €24.7 million (US$32.5 million) in an offering on the NYSE Euronext Exchanges in Brussels and Paris.
Shares in Basilea Pharmaceutica AG gained as much as 6 percent during mid-morning trading Tuesday on news that it secured a contract from the U.S. Biomedical Advanced Research and Development Authority (BARDA), worth up to $89 million, for the development of its antibiotic, BAL30072.
Shares in Basilea Pharmaceutica AG gained as much as 6 percent during mid-morning trading Tuesday on news that it secured a contract from the U.S. Biomedical Advanced Research and Development Authority (BARDA), worth up to $89 million, for the development of its antibiotic, BAL30072.
Vasopharm GmbH raised €5 million (US$6.5 million) in new investment to fund preparations for a Phase III trial of VAS203, an allosteric inhibitor of nitric oxide (NO) synthase in development for treating traumatic brain injury (TBI).
Cardio3 Biosciences SA is the third European biotechnology company to dip its toes in the initial public offering (IPO) waters this year. The Belgian stem cell therapy developer is seeking up to €24.7 million (US$32.5 million) in an offering on the NYSE Euronext Exchanges in Brussels and Paris.
Valneva SE priced its previously flagged and fully underwritten €40 million (US$53.3 million) rights issue at €2.65 per share, a steep discount on the company's prevailing share price of €4.61 immediately prior to the final pricing decision.
DUBLIN, Ireland – In a sharp slap in the face to the company's management and its would-be acquirer Royalty Pharma, shareholders in Elan Corp. plc voted down three of four motions tabled at an extraordinary general meeting Monday.
